Documentos de Javier Gilbert Jaramillo | REDI

Regresar

Mostrando 2 resultados de: 2

Filtros aplicados

Publisher: "Cell"

Subtipo de publicación

Área temáticas

Enfermedades(1)

Farmacología y terapéutica(1)

Medicina y salud(1)

Microorganismos, hongos y algas(1)

Área de conocimiento

Inmunología(2)

Año de Publicación

Origen

Palabras Claves

Neutralization(1)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Abstract: Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the

Palabras claves:

antibody, B cell, BNT162b2, covid-19, dosing interval, Neutralization, SARS-COV-2, T cell, Vaccine, variants of concern

Abuelgasim H., Adele S., Adland E., Adlou S., Akther H.D., Al-Taei S., Alhussni A., Ali M., Altmann T., Amini A., Angyal A., Arancibia-Cárcamo C.V., Austin J.A., Azim Ansari M., Barnes E., Bayley M., Bridges-Webb A., Brown A., Brown H., Brown R., Carroll M.W., Chalk J., Chand M., Chawla A., Chinnakannan S., Conlon C.P., Cross A., Cutteridge J., de Lara C., de Silva T.I., Deeks A.S., Dejnirattisai W., Denly L., Diffey B., Dimitriadis S., Dobson S.L., Dold C., Donnison T., Drake T.M., Dunachie S.J., Duncan C.J.A., Dupont M., Eyre D.W., Fairman A., Faustini S., Foulkes S., Frater J., Gardiner S., Gillson N., Goulder P., Hackstein C.P., Hall V., Hambleton S., Haniffa M., Hargreaves A., Haworth J., Hering L.M., Holmes J., Hopkins S., Horner E., Hornsby H., Jämsén A., Javier Gilbert Jaramillo, Jeffery K., Johnson S.A., Jones C., Kasanyinga M., Kelly S., Kilby J.A., Kirk R., Klenerman P., Knight M.L., Lawrie A., Lee L., Linder A., Longet S., Malone T., Matthews P.C., Meardon N., Mongkolsapaya J., Moore S.C., Nicols A.R., Payne R.P., Phillips E., Pollard A.J., Reyes L.S., Richter A., Rowland-Jones S.L., Saei A., Sandhar G., Screaton G.R., Shields A., Skelly D.T., Stafford L., Supasa P., Tipton T., Turtle L., Tyerman J.K., Whitham R., Wootton D.G.

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Abstract: Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency use as therap

Palabras claves:

coronavirus, SARS-CoV-2, anti-RBD antibody, receptor binding domain, antibody, immune responses, virus structure

Bailey A.L., Bertram F.K.R., Bolton J., Carroll M.W., Case J.B., Chen R.E., Clare D.K., Dejnirattisai W., Diamond M.S., Dold C., Dong T., Duyvesteyn H.M.E., Fry E.E., Fyfe A., Ginn H.M., Gupta S., Hall D.R., Howe A., Huang K.Y.A., James W.S., Javier Gilbert Jaramillo, Kafai N.M., Klenerman P., Knight J.C., Knight M.L., Levin R., Liu C., López-Camacho C., Mentzer A.J., Mongkolsapaya J., Paesen G.C., Paterson N.G., Peng Y., Pollard A.J., Radecke J., Ren J., Screaton G.R., Siebert C.A., Skelly D.T., Slon-Campos J., Song Y., Stuart D.I., Supasa P., Tan T.K., Temperton N.J., Thompson C., Townsend A.R., Walter T.S., Wang B., Williams M.A., Ying B., Zhao Y., Zhou D.